MedTrace Logo

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2015-03-06

Study results available
· View outcomes & findings →

Summary

Evaluation of the ocular safety and efficacy of a drug delivery system in open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

High Dose Drug Device

device inserted for 4 days

DRUG

Low Dose Drug Device

device inserted for 4 days

DRUG

Placebo Device

device inserted for 4 days

DRUG

bimatoprost 0.03%

one drop in each eye on one day only

Sponsors & Collaborators

  • Vistakon Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01016691 on ClinicalTrials.gov